76 related articles for article (PubMed ID: 15801928)
1. Infliximab and the bone in Crohn's disease.
Franchimont N; Reenaers C; Louis E
Aliment Pharmacol Ther; 2005 Apr; 21(7):918-9. PubMed ID: 15801928
[No Abstract] [Full Text] [Related]
2. Infliximab and the bone in Crohn's disease.
Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
[No Abstract] [Full Text] [Related]
3. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
4. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Thayu M; Leonard MB; Hyams JS; Crandall WV; Kugathasan S; Otley AR; Olson A; Johanns J; Marano CW; Heuschkel RB; Veereman-Wauters G; Griffiths AM; Baldassano RN;
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1378-84. PubMed ID: 19081527
[TBL] [Abstract][Full Text] [Related]
5. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
Bernstein M; Irwin S; Greenberg GR
Am J Gastroenterol; 2005 Sep; 100(9):2031-5. PubMed ID: 16128948
[TBL] [Abstract][Full Text] [Related]
6. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
7. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
8. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
10. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
11. [Infliximab--practical guidelines for the treatment of Crohn's disease].
Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
13. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
14. The Dutch guidelines for treatment with infliximab for Crohn's disease.
Vermeire S
Neth J Med; 2006; 64(7):210-1. PubMed ID: 16929081
[No Abstract] [Full Text] [Related]
15. Steroid-independent Crohn's disease patients also benefit from combination therapy of infliximab plus azathioprine.
van den Brande JM; Peppelenbosch MP; Hommes DW
Gastroenterology; 2006 Oct; 131(4):1362-3. PubMed ID: 17030216
[No Abstract] [Full Text] [Related]
16. Infliximab therapy in Crohn's disease: a pragmatic approach?
Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to infliximab in Crohn's disease.
Chaudhary R; Ghosh S
Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
[No Abstract] [Full Text] [Related]
19. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
[TBL] [Abstract][Full Text] [Related]
20. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
Pazianas M; Rhim AD; Weinberg AM; Su C; Lichtenstein GR
Ann N Y Acad Sci; 2006 Apr; 1068():543-56. PubMed ID: 16831950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
